SINTEF is a non-profit independent research organization, and with approx. 2200 employees, one of the largest in Europe. SINTEF performs contract research and development for a wide range of both Norwegian and international industry customers and participates as a research partner in publicly funded research projects, both at the national and to a large degree at the EU level. Annual revenues for SINTEF are more than 300 M€.

The Department of Biotechnology and Nanomedicine is coordinator of LeadtoTreat with its extensive experience and significant ongoing project activity on synthesis and characterisation of nanomedicines. SINTEF was a core partner and assay group leader in the Horizon 2020 infrastructure project European Nanomedicine Characterization Laboratory (EUNCL) and is a key player in a range of international and national projects focusing on development and preclinical characterization of nanomedicines and nano-enabled medical devices. State-of-the art instrumentation is available for physicochemical and chemical analyses, as well as high-throughput advanced in vitro analyses, both 2D and 3D cell-based assays. Analytical facilities and competence are also widely used for classical pharmaceutical, small molecule and protein analyses. Also, the department has high competence in biotechnological processes, molecular genetics, bioinformatics and translation from lab to pilot scale. The Department of Biotechnology and Nanomedicine has also had a strong standing activity in drug development and natural compound discovery and is the IP owner of the antibiotic compound MBL-AB01 which will be included for proof of principle in the LeadtoTreat project.


Geir Klingenberg photo
Geir Klingenberg
Project Coordinator
Ruth Schmid photo
Ruth Schmid
Senior Research Scientist